Strategic acquisitions DCR expanded capabilities through acquiring MedSleuth in 2022, signaling a growth trajectory and expanded pharmacovigilance or trial analytics capabilities that can be cross-sell to pharma and biotech clients.

Alliance network The Alliance Site Network launched in 2017 indicates a scalable site protocol for early stage CKD trials, presenting a ready-made network to accelerate new kidney-related studies for sponsors.

Phase II-III focus With specialized multi‑specialty Phase II–III clinical trial services and a track record of over 500 trials across 175+ pharma companies, there is a proven platform for expanding current sponsor programs or adding new therapeutic areas.

Strategic partnerships Past collaborations with Quintiles and the DaVita health ecosystem position DCR as a bridge between kidney care and full product development, offering co‑selling opportunities with large CROs and sponsor teams.

Financial stability Revenue in the mid‑hundred million range and a focused, lean Employee base suggest an agile partner for mid‑size sponsors seeking high‑quality, cost‑effective Phase II–III execution without onboarding of large, sprawling CROs.